Completed PHASE2 INTERVENTIONAL NCT00324779

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Multicenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before Chemotherapy

Sponsor: University Hospital Erlangen

Interventions rituximab

Updated 6 times since 2017 Last updated: Sep 24, 2015 Started: Mar 31, 2004 Primary completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00324779, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by University Hospital Erlangen, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Erlangen

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Augsburg, Germany , Berlin, Germany , Biefeld, Germany , Bremen, Germany , Cologne, Germany , Datteln, Germany , Dresden, Germany , Erfurt, Germany , Erlangen, Germany and 26 more locations